Table 2. Demographic and clinical parameters of both patient groups.
| Clinical characteristics | ICD therapy | No ICD | Odds ration | p-value |
| n = 12 | therapy n = 14 | (95% CI) | ||
| Men | 11 | 10 | 4.4 (0.42, 46.3) | 0.217 |
| Family history of ARVC | 1 | 3 | 0.33 (0.03, 3.72) | 0.372 |
| Age at diagnosis (years) | 39.5 | 39.5 | 1.00 (0.94, 1.06) | 0.968 |
| (35.0, 54.0) | (36.8, 48.5) | |||
| Follow-up duration (years) | 14±10 | 9.8±9.7 | 1.01 (0.99, 1.02) | 0.202 |
| Symptoms at time of | ||||
| ARVC diagnosis | ||||
| - aborted SCD | 3 | 1 | 4.0 (0.36, 45.1) | 0.262 |
| - syncope | 3 | 9 | 0.11 (0.018, 0.7) | 0.020 |
| - heart failure | 1 | 0 | 0.28 | 0.48 |
| (0.01, 7.67)fis* | ||||
| - VT | 10 | 9 | 2.22 (0.33, 15.18) | 0.415 |
| History of heart failure | 4 | 0 | 15.35 | 0.033* |
| (0.73, 321.60)* | ||||
| Arrhythmia | ||||
| - AFib or flutter | 2 | 1 | 0.60 (0.047, 7.63) | 0.694 |
| - VT | 8 | 7 | 0.667 (0.13, 3.35) | 0.622 |
| - Other (WPW, AVNRT) | 2 | 1 | 0.60 (0.047, 7.63) | 0.694 |
| Drug therapy | ||||
| - betablocker | 9 | 5 | 0.397 (0.08, 1.94) | 0.253 |
| - Amiodarone | 3 | 2 | 0.227 (0.022, 2.4) | 0.217 |
| - ACEI or ARB | 4 | 1 | 0.227 (0.022, 2.4) | 0.217 |
| ICD | ||||
| - primary prevention (vs | 0 | 2 | 2.78 (0.1, 74.7) | 0.99 |
| secondary) | ||||
| - time from ARVC | 3.25 | 0.06 | 0.90 (0.76, 1.06) | 0.19 (0.067 M–W) |
| diagnosis to ICD | (0.06, 21.5) | (0.004, 1.23) | ||
| implantation (years) | ||||
| - age at time of | 52 | 39 | 1.075 | 0.063(0.053 M–W) |
| implantation | (39.3, 60.5) | (34.8, 50.5) | (0.996, 1.16) |
*
p-values based on Fishers exact testing.
Summaries within groups are given as number with the feature for categoric variables and median (inter-quartile range) for numeric data.
(VT: ventricular tachycardia; WPW: Wolff-Parkinson-White-Syndrome; AVNRT: atrioventricular nodal re-entrant tachycardia; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker).